| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794326 | Ophthalmology | 2017 | 10 Pages |
Abstract
Level I evidence supports the use of atropine to prevent myopic progression. Although there are reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low doses (especially atropine 0.01%).
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Stacy L. MD, Raymond T. MSPH, Deborah K. MD, Amy K. MD, Jennifer A. MD, Lorri B. MD, Scott R. MD,